Meningococcal Surveillance Australia: Reporting period 1 January to 31 March 2024

Commun Dis Intell (2018). 2024 Nov 21:48. doi: 10.33321/cdi.2024.48.53.

Abstract

The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year is contained in the AMSP annual reports.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Australia / epidemiology
  • Ceftriaxone
  • Ciprofloxacin / pharmacology
  • Drug Resistance, Bacterial
  • Humans
  • Meningococcal Infections* / epidemiology
  • Meningococcal Infections* / microbiology
  • Neisseria meningitidis* / drug effects
  • Penicillins / pharmacology
  • Population Surveillance
  • Rifampin / pharmacology
  • Rifampin / therapeutic use
  • Serogroup

Substances

  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Penicillins
  • Rifampin
  • Ceftriaxone